Most Effective Meds for Alcohol Use Disorder Flagged

TOPLINE:

In conjunction with psychosocial interventions, oral naltrexone and acamprosate are both effective first-line drug therapies for alcohol use disorder (AUD), results of a systematic review and meta-analysis found.

METHODOLOGY:

• Researchers evaluated efficacy and comparative efficacy of three therapies for AUD that are approved in the United States (acamprosate, naltrexone, and disulfiram) and six that are commonly used off-label (baclofen, gabapentin, varenicline, topiramate, prazosin, and ondansetron).
• Data came from 118 randomized clinical trials lasting at least 12 weeks with 20,976 participants.
• 74% of these studies included psychosocial co-interventions, and the primary outcome was alcohol consumption.
• Numbers needed to treat (NNT) were calculated for medications with at least moderate strength of evidence for benefit.

TAKEAWAY:

• Acamprosate (NNT = 11) and naltrexone (50 mg/d; NNT = 18) had the highest strength of evidence and were both associated with statistically significant improvement in drinking outcomes.
• Oral naltrexone but not acamprosate was also associated with lower rates of return to heavy drinking (NNT = 11) compared with placebo.
• Injectable naltrexone was not associated with return to any or heavy drinking but was associated with fewer drinking days over the 30-day treatment period (weighted mean difference, -4.99 days).
• The four trials that directly compared acamprosate with oral naltrexone did not consistently establish superiority of either medication for alcohol use outcomes, and among off-label drugs, only topiramate had moderate strength of evidence for benefit.

IN PRACTICE:

“Alcohol use disorder affects more than 28.3 million people in the United States and is associated with increased rates of morbidity and mortality. In conjunction with psychosocial interventions, these findings support the use of oral naltrexone, 50 mg/d, and acamprosate as first-line pharmacotherapies for alcohol use disorder,” the authors write.

SOURCE:

The study, with first author Melissa McPheeters, PhD, MPH, RTI International, Research Triangle Park, North Carolina, was published online November 7, 2023 in JAMA.

LIMITATIONS:

Most study participants had moderate to severe AUD, and the applicability of the findings to people with mild AUD is uncertain. The mean age of participants was typically between ages 40 and 49 years, and it’s unclear whether the medications have similar efficacy for older or younger age groups. Information on adverse effects was limited.

DISCLOSURES:

Funding for the study was provided by the Agency for Healthcare Research and Quality of the US Department of Health and Human Services. The authors have disclosed no relevant conflicts of interest.

SDGs, Targets, and Indicators

1. Which SDGs are addressed or connected to the issues highlighted in the article?

• SDG 3: Good Health and Well-being

The article discusses the effectiveness of drug therapies for alcohol use disorder (AUD), which is related to promoting good health and well-being.

2. What specific targets under those SDGs can be identified based on the article’s content?

• Target 3.5: Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol

The article focuses on evaluating the efficacy of different drug therapies for AUD, aligning with the target of strengthening the treatment of substance abuse.

3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?

• Numbers needed to treat (NNT): The article mentions the NNT values for different medications, which can be used as an indicator to measure the effectiveness of drug therapies for AUD.
• Improvement in drinking outcomes: The article states that both acamprosate and naltrexone were associated with statistically significant improvement in drinking outcomes, indicating progress towards the target of strengthening treatment for substance abuse.
• Rates of return to heavy drinking: The article mentions that oral naltrexone was associated with lower rates of return to heavy drinking compared to placebo, which can be used as an indicator of treatment effectiveness.
• Number of drinking days over the treatment period: The article states that injectable naltrexone was associated with fewer drinking days over the 30-day treatment period, which can be used as an indicator of treatment effectiveness.

Table: SDGs, Targets, and Indicators

Behold! This splendid article springs forth from the wellspring of knowledge, shaped by a wondrous proprietary AI technology that delved into a vast ocean of data, illuminating the path towards the Sustainable Development Goals. Remember that all rights are reserved by SDG Investors LLC, empowering us to champion progress together.

Source: medscape.com

Join us, as fellow seekers of change, on a transformative journey at https://sdgtalks.ai/welcome, where you can become a member and actively contribute to shaping a brighter future.